The FDA yesterday approved Foundayo (orforglipron), Eli Lilly's oral GLP-1 for weight loss. It's the second daily GLP-1 pill to reach the market, following Novo Nordisk's Wegovy pill in December 2025.
For anyone tracking the GLP-1 landscape from an employer benefits perspective, this approval matters — not because of the drug itself, but because of what it signals about where utilization and cost are headed.
What's New About Foundayo
Foundayo is a once-daily pill approved for adults with obesity or those who are overweight with at least one weight-related comorbidity. In Eli Lilly's clinical trials, participants on the highest dose lost an average of 12.4% of their body weight over 72 weeks.
The headline for patients is convenience. Unlike the Wegovy pill — which must be taken in the morning, on an empty stomach, with a 30-minute wait before eating — Foundayo can be taken at any time of day, with or without food. That's a meaningful difference for adherence. It removes one of the most common complaints about oral GLP-1 therapy.
There's also a potential manufacturing advantage. As a small molecule rather than a peptide, Foundayo may be easier to produce at scale than oral semaglutide. Supply constraints have been a recurring issue in the GLP-1 market, and a simpler manufacturing process could help Lilly keep pace with demand — though how that plays out in practice remains to be seen.
Pricing starts at $149/month for the lowest dose without insurance. With commercial coverage, patients may pay as little as $25/month through a Lilly savings card. According to Lilly, eligible Medicare Part D individuals may be able to access the drug for $50/month beginning as soon as July 1, 2026.
Lilly says it will begin shipping Foundayo on April 6.
The Employer Utilization Question
Here's the part that matters most for benefits leaders.
The Wegovy pill reached an estimated 400,000 users in its first 10 weeks — described by some analysts as the fastest drug launch in history. Now there's a second oral option with fewer dosing restrictions, competitive pricing, and a manufacturer that estimates fewer than one in 10 people who could benefit from GLP-1 therapy are currently taking one.
Every barrier that was naturally throttling GLP-1 utilization is falling. Needles — gone, with two pill options now available. Cold storage requirements — gone for oral formulations. Dosing complexity — reduced with Foundayo's flexible timing. Price — coming down through manufacturer pricing deals and the Medicare $50/month copay program launching in July.
All of this is good for patients who need these medications. But for self-funded employers already managing rising GLP-1 costs, the utilization trajectory just steepened.
The Peterson-KFF employer focus groups found that large employers are already seeing higher-than-expected GLP-1 utilization and significant prescription drug spending impacts. Some have pulled back coverage entirely. Others have implemented prior authorization, step therapy, or lifestyle program requirements.
A second oral GLP-1 doesn't change the calculation for those employers. It accelerates it.
The Durability Question Hasn't Changed
What's notable about the Foundayo approval — from a benefits design perspective — is what it doesn't address.
The Oxford BMJ meta-analysis (West et al., 2026) found that weight regain after discontinuing GLP-1s was roughly four times faster than after behavioral interventions, with an average return to baseline weight of 1.7 years. That data applies to the drug class, not to any specific product. A more convenient pill doesn't change the underlying biology of what happens when patients stop treatment.
Lilly has published data showing Foundayo helped maintain weight loss when patients switched from injectable GLP-1s to the pill — which is promising for continuity within pharmacotherapy. But the broader durability question — what happens when patients stop GLP-1s entirely, by choice, cost, or necessity — remains unanswered by the drug alone.
More access to GLP-1s is a good thing. More options for patients are a good thing. But more prescriptions without a plan for what comes after doesn't solve the structural problem employers are facing. It makes the problem larger.
What Employers Should Be Thinking About
For benefits leaders reviewing GLP-1 coverage in light of this approval, a few considerations:
Expect utilization to climb. A second oral option with easier dosing and aggressive pricing will drive new prescriptions. If your plan covers GLP-1s for weight loss, model for higher uptake than you've seen to date.
Evaluate your plan design now, not at renewal. The window between Foundayo's approval and its impact on your pharmacy spend is weeks, not months. Employers who haven't revisited their GLP-1 benefit design — including prior authorization criteria, step therapy requirements, and lifestyle program integration — should do so before utilization surprises them.
The maintenance layer matters more, not less. As access expands, the population of employees who start and eventually stop GLP-1 therapy will grow. Programs that help employees build sustainable dietary patterns and metabolic awareness — whether alongside medication or independently — become more important as the on-ramp widens.
The on-ramp to GLP-1 therapy has never been wider. The question we raised last week still stands: what's the off-ramp?